Transcend Capital Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Transcend Capital Advisors’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,372	Closed	-$238K	–	606
2024 Q3	$238K	Sell	3,372 -1	-0%	-$70	0.02%	532
2024 Q2	$224K	Buy	3,373 +1	+0%	+$66	0.02%	529
2024 Q1	$229K	Hold	3,372	–	–	0.02%	475
2023 Q4	$208K	Buy	+3,372	New	+$198K	0.02%	463
2023 Q3	–	Sell	-3,372	Closed	-$201K	–	503
2023 Q2	$201K	Buy	+3,372	New	+$200K	0.02%	455
2023 Q1	–	Sell	-3,372	Closed	-$209K	–	506
2022 Q4	$209K	Buy	+3,372	New	+$203K	0.02%	441
2022 Q3	–	Sell	-3,372	Closed	-$215K	–	502
2022 Q2	$215K	Buy	3,372 +45	+1%	+$2.86K	0.02%	442
2022 Q1	$215K	Hold	3,327	–	–	0.02%	462
2021 Q4	$221K	Hold	3,327	–	–	0.02%	438
2021 Q3	$208K	Hold	3,327	–	–	0.02%	451
2021 Q2	$206K	Buy	+3,327	New	+$202K	0.03%	305

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Transcend Capital Advisors's IHE Position: Q4 2024 in Review

Transcend Capital Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2024, closing a stake of 3,372 shares — an estimated $238K sold.

Transcend Capital Advisors first reported a position in IHE in Q2 2021 and held it in 11 quarters. The position peaked at $238K in Q3 2024. 155 funds tracked by Wall St. Rank hold IHE as of Q4 2024.

Transcend Capital Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2024 after selling out during the quarter.
Transcend Capital Advisors sold 3,372 iShares US Pharmaceuticals ETF shares in Q4 2024, an estimated $238K.
Transcend Capital Advisors first reported a position in iShares US Pharmaceuticals ETF in Q2 2021 and held it in 11 quarters.
Transcend Capital Advisors's iShares US Pharmaceuticals ETF position peaked at $238K in Q3 2024.
155 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2024.

Based on Transcend Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.